RedHill Biopharma (RDHL) announced the mutual decision with Cosmo Technologies to voluntary terminate the U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea. The license agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
RedHill said it will cease any Aemcolo commercialization of Aemcolo upon termination of the license agreement. All rights previously ascribed in the license agreement to RedHill will revert to Cosmo.
Rick Scruggs, RedHill's Chief Commercial Officer, said: "This decision was made following careful mutual consideration."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.